Developing a vaccine to prevent Chlamydia infections
MOMP-based recombinant antigens for a Chlamydia vaccine
This study is working on a new vaccine to help protect people from Chlamydia, a common sexually transmitted infection, by using parts of the bacteria that can boost the immune system to fight it off better.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tufts University Boston NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10471957 on NIH RePORTER |
What this research studies
This research aims to create a vaccine against Chlamydia trachomatis, the leading cause of bacterial sexually transmitted infections. The project focuses on the major outer membrane protein (MOMP) of the bacteria, which has unique regions that can stimulate the immune system to produce protective responses. By identifying and utilizing specific parts of the MOMP, the researchers hope to develop a vaccine that provides broad protection against various strains of Chlamydia. This approach addresses the limitations of previous vaccines and aims to prevent recurring infections that antibiotics cannot stop.
Who could benefit from this research
Good fit: Ideal candidates for this research are sexually active individuals, particularly women, who are at risk of Chlamydia infections.
Not a fit: Patients who are not sexually active or those who have already been vaccinated against Chlamydia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of Chlamydia infections and their associated complications, such as infertility.
How similar studies have performed: While previous attempts at developing Chlamydia vaccines have shown limited success, this approach using MOMP is innovative and aims to overcome past challenges.
Where this research is happening
Boston, United States
- Tufts University Boston — Boston, United States (Active)
Researchers
- Principal investigator: Massari, Paola — Tufts University Boston
- Study coordinator: Massari, Paola
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.